1053 related articles for article (PubMed ID: 32200389)
1. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
Chen X; Wang L; Lou J
Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
Cheng F; Su L; Qian C
Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
[TBL] [Abstract][Full Text] [Related]
3. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
Alix-Panabières C; Pantel K
Cancer Discov; 2016 May; 6(5):479-91. PubMed ID: 26969689
[TBL] [Abstract][Full Text] [Related]
4. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
[TBL] [Abstract][Full Text] [Related]
5. Liquid biopsies.
Lianidou E; Pantel K
Genes Chromosomes Cancer; 2019 Apr; 58(4):219-232. PubMed ID: 30382599
[TBL] [Abstract][Full Text] [Related]
6. Genetic profiling of cancer with circulating tumor DNA analysis.
Lu L; Bi J; Bao L
J Genet Genomics; 2018 Feb; 45(2):79-85. PubMed ID: 29502957
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine.
Batth IS; Mitra A; Manier S; Ghobrial IM; Menter D; Kopetz S; Li S
Ann Oncol; 2017 Mar; 28(3):468-477. PubMed ID: 27998963
[TBL] [Abstract][Full Text] [Related]
8. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
Fici P
Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
[TBL] [Abstract][Full Text] [Related]
9. Liquid biopsy of circulating tumor DNA and biosensor applications.
Li X; Ye M; Zhang W; Tan D; Jaffrezic-Renault N; Yang X; Guo Z
Biosens Bioelectron; 2019 Feb; 126():596-607. PubMed ID: 30502682
[TBL] [Abstract][Full Text] [Related]
10. How liquid biopsies can change clinical practice in oncology.
Siravegna G; Mussolin B; Venesio T; Marsoni S; Seoane J; Dive C; Papadopoulos N; Kopetz S; Corcoran RB; Siu LL; Bardelli A
Ann Oncol; 2019 Oct; 30(10):1580-1590. PubMed ID: 31373349
[TBL] [Abstract][Full Text] [Related]
11. Technical considerations for circulating tumor DNA detection in oncology.
Franczak C; Filhine-Tresarrieu P; Gilson P; Merlin JL; Au L; Harlé A
Expert Rev Mol Diagn; 2019 Feb; 19(2):121-135. PubMed ID: 30648442
[TBL] [Abstract][Full Text] [Related]
12. The feasibility of using mutation detection in ctDNA to assess tumor dynamics.
Yi X; Ma J; Guan Y; Chen R; Yang L; Xia X
Int J Cancer; 2017 Jun; 140(12):2642-2647. PubMed ID: 28124376
[TBL] [Abstract][Full Text] [Related]
13. Liquid biopsy in breast cancer: A comprehensive review.
Alimirzaie S; Bagherzadeh M; Akbari MR
Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
[TBL] [Abstract][Full Text] [Related]
14. Dynamic Treatment Stratification Using ctDNA.
Vidal J; Taus A; Montagut C
Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
[TBL] [Abstract][Full Text] [Related]
15. Detection of incipient tumours by screening of circulating plasma DNA: hype or hope?
Lenaerts L; Tuveri S; Jatsenko T; Amant F; Vermeesch JR
Acta Clin Belg; 2020 Feb; 75(1):9-18. PubMed ID: 31578135
[No Abstract] [Full Text] [Related]
16. Liquid Biopsy: Approaches to Dynamic Genotyping in Cancer.
von Bubnoff N
Oncol Res Treat; 2017; 40(7-8):409-416. PubMed ID: 28693026
[TBL] [Abstract][Full Text] [Related]
17. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
[TBL] [Abstract][Full Text] [Related]
18.
Mastoraki S; Strati A; Tzanikou E; Chimonidou M; Politaki E; Voutsina A; Psyrri A; Georgoulias V; Lianidou E
Clin Cancer Res; 2018 Mar; 24(6):1500-1510. PubMed ID: 29284708
[No Abstract] [Full Text] [Related]
19. Considerations for the use of circulating tumor DNA sequencing as a screening tool in cancer predisposition syndromes.
Paramathas S; Guha T; Pugh TJ; Malkin D; Villani A
Pediatr Blood Cancer; 2020 Dec; 67(12):e28758. PubMed ID: 33047872
[TBL] [Abstract][Full Text] [Related]
20. Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection.
Fiala C; Diamandis EP
BMC Med; 2018 Oct; 16(1):166. PubMed ID: 30285732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
